In the cardiovascular field, it has been shown that some HDAC inhibitors, such as Trichostatin A (TSA), Vorinostat (SAHA), and valproic acid (VPA), have specific protective effects against cardiac hypertrophy, heart failure, atherosclerosis, and ischemia/reperfusion injury, as shown in Table 2. The gene discussed is HDAC9; the disease is cardiac hypertrophy.